12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

TH-302 regulatory update

The European Commission granted Orphan Drug designation for Threshold's TH-302 to treat soft tissue sarcoma (STS). The compound is in...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >